Allergy Relief 24hr
Levocetirizine Dihydrochloride
Velocity Pharma Llc
Human Otc Drug
NDC 76168-501Allergy Relief 24hr also known as Levocetirizine Dihydrochloride is a human otc drug labeled by 'Velocity Pharma Llc'. National Drug Code (NDC) number for Allergy Relief 24hr is 76168-501. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Allergy Relief 24hr drug includes Levocetirizine Dihydrochloride - 5 mg/1 . The currest status of Allergy Relief 24hr drug is Active.
Drug Information:
| Drug NDC: | 76168-501 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Allergy Relief 24hr |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Levocetirizine Dihydrochloride |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Velocity Pharma Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Tablet |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | LEVOCETIRIZINE DIHYDROCHLORIDE - 5 mg/1
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | ANDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 02 Jul, 2019 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 25 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | ANDA211551 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | VELOCITY PHARMA LLC
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 855172
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | SOD6A38AGA
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class: | Histamine H1 Receptor Antagonists [MoA]
Histamine-1 Receptor Antagonist [EPC]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 76168-501-10 | 1 BOTTLE in 1 CARTON (76168-501-10) / 10 TABLET in 1 BOTTLE | 02 Jul, 2019 | N/A | No |
| 76168-501-11 | 1 BOTTLE in 1 CARTON (76168-501-11) / 100 TABLET in 1 BOTTLE | 13 Dec, 2019 | N/A | No |
| 76168-501-18 | 1 BOTTLE in 1 CARTON (76168-501-18) / 180 TABLET in 1 BOTTLE | 13 Dec, 2019 | N/A | No |
| 76168-501-24 | 1 BOTTLE in 1 CARTON (76168-501-24) / 240 TABLET in 1 BOTTLE | 13 Dec, 2019 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose antihistamine
Product Elements:
Allergy relief 24hr levocetirizine dihydrochloride hypromelloses lactose monohydrate magnesium stearate microcrystalline cellulose polyethylene glycol 400 titanium dioxide levocetirizine dihydrochloride levocetirizine x;x
Indications and Usage:
Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
Warnings:
Warnings do not use if you have kidney disease if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing cetirizine ask a doctor before use if you have ever had trouble urinating or emptying your bladder when using this product drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery stop use and ask a doctor if you have trouble urinating or emptying your bladder an allergic reaction to this product occurs. seek medical help right away. if pregnant or breast-feeding: if breast-feeding: not recommended if pregnant: ask a health professional before use keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away (1-800-222-1222).
Do Not Use:
Warnings do not use if you have kidney disease if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing cetirizine ask a doctor before use if you have ever had trouble urinating or emptying your bladder when using this product drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery stop use and ask a doctor if you have trouble urinating or emptying your bladder an allergic reaction to this product occurs. seek medical help right away. if pregnant or breast-feeding: if breast-feeding: not recommended if pregnant: ask a health professional before use keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away (1-800-222-1222).
When Using:
When using this product drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery
Dosage and Administration:
Directions adults 65 years of age and older â ask a doctor adults and children 12-64 years of age â take 1 tablet (5 mg) once daily in the evening â do not take more than 1 tablet (5 mg) in 24 hours â ½ tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms children 6-11 years of age â take ½ tablet (2.5 mg) once daily in the evening â do not take more than ½ tablet (2.5 mg) in 24 hours children under 6 years of age â do not use consumers with kidney disease â do not use (note: age ranges are bolded in the draft container labeling for tablet bottle )
Stop Use:
Stop use and ask a doctor if you have trouble urinating or emptying your bladder an allergic reaction to this product occurs. seek medical help right away.
Package Label Principal Display Panel:
Principal display panel label for allergy relief 180 tablets in a bottle label for allergy relief 10 tablets in a bottle untitled capture10
Further Questions:
Questions or comments? call 1-855-314 -1850